WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 1 fonti

Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more

Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review program

Raccontata dastatnews.com

Timeline cronologica

  1. martedì 2 giugno 2026·statnews.com

    Pharmalittle: We're reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more

    Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks

  2. mercoledì 3 giugno 2026·statnews.com

    Pharmalittle: We're reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more

    Taking weight loss drugs for at least three years could prevent thousands of knee replacements a year, a new study found

  3. giovedì 4 giugno 2026·statnews.com

    Pharmalittle: We're reading about fewer pharma investments in Germany, growing U.S. layoffs, and more

    Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law

  4. venerdì 5 giugno 2026·statnews.com

    Pharmalittle: We're reading about Roche accusing U.S. of 'blackmail,' a ruling on skinny labels, and more

    Drugmakers and patient groups asked the FDA to pause former commissioner Marty Markary's National Priority Voucher drug review program